PCM
NUVB icon

Prelude Capital Management’s Nuvation Bio NUVB Stock Holding History

Prelude Capital Management’s Portfolio NUVB Stock Details NUVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$622K Buy
109,567
+95,984
+707% +$469K 0.05% 438
2026
Q1 		$58.3K Buy
+13,583
New +$75.7K ﹤0.01% 1114
2024
Q3 		– Sell
-36,440
Closed -$106K – 1476
2024
Q2 		$106K Sell
36,440
-12,760
-26% -$38.9K 0.01% 1093
2024
Q1 		$179K Buy
+49,200
New +$94.5K 0.01% 1131
2023
Q4 		– Sell
-32,932
Closed -$44.1K – 1261
2023
Q3 		$44.1K Sell
32,932
-32,572
-50% -$54.2K ﹤0.01% 1053
2023
Q2 		$118K Sell
65,504
-8,271
-11% -$14.1K 0.01% 911
2023
Q1 		$122K Sell
73,775
-2,429
-3% -$4.92K 0.01% 933
2022
Q4 		$146K Buy
76,204
+23,500
+45% +$47.5K 0.01% 1018
2022
Q3 		$118K Buy
+52,704
New +$150K ﹤0.01% 1152
2021
Q2 		– Sell
-12,762
Closed -$133K – 1864
2021
Q1 		$133K Buy
+12,762
New +$143K ﹤0.01% 1389

Other funds holding NUVB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
DFO
Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Prelude Capital Management's NUVB Position: Q2 2026 in Review

Prelude Capital Management increased its Nuvation Bio (NUVB) stake by 707% in Q2 2026, buying an estimated $469K and bringing the position to 109,567 shares worth $622K. The position accounts for 0.05% of the portfolio, ranked #438.

Prelude Capital Management first reported a position in NUVB in Q1 2021 and has held it in 10 quarters since. 244 funds tracked by Wall St. Rank hold NUVB as of Q2 2026.

  • Prelude Capital Management held 109,567 shares of Nuvation Bio worth $622K as of Q2 2026.
  • Prelude Capital Management bought 95,984 Nuvation Bio shares in Q2 2026, an estimated $469K.
  • Nuvation Bio made up 0.05% of Prelude Capital Management's portfolio in Q2 2026, its #438 holding.
  • Prelude Capital Management first reported a position in Nuvation Bio in Q1 2021 and has held it in 10 quarters since.
  • 244 funds tracked by Wall St. Rank held Nuvation Bio as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.